IL6 and cancer: In subgroup of patients with high grade tumor (n = 84), the patients with high STAT3 tumor had a significantly higher risk of both disease progression (p = 0.008) and cancer-specific mortality (p = 0.008), but not with tumors expressing high S1PR1 (p = 0.257 and p = 0.161, respectively) or high IL-6 (p = 0.395 and p = 0.250, respectively).